Processa pharmaceuticals to participate in a panel on interaction with the fda at the world orphan drug congress

Company also to provide a corporate overview in a separate session hanover, md, may 22, 2023 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, today announces ceo david young, pharm.d., ph.d. will participate in a panel at the world orphan drug congress to be held at the gaylord national resort & convention center in washington, d.c.
PCSA Ratings Summary
PCSA Quant Ranking